Teva Fined $503 Million for Delaying Multiple Sclerosis Drug; $49 Million Settlements in Pennsylvania with Heritage, Apotex

Teva Pharmaceutical, the world’s largest generic drugmaker, has been fined $503 million by European antitrust regulators for stifling competition related to a popular multiple sclerosis medication. In a separate development, Attorney General Anthony G. Brown announced two significant settlements with Heritage Pharmaceuticals and Apotex, amounting to a total of $49.1 million. These settlements address allegations of price inflation and manipulation of generic prescription drugs. Additionally, consumers in Pennsylvania who purchased certain generic drugs between 2010 and 2016 may be eligible for refunds due to this multistate settlement involving the two pharmaceutical companies.